Påviste Aspergillus- infektioner blev observeret hos 1 versus 7 patienter og påvist, eller mulig udvikling af Candida- infektioner blev observeret i henholdsvis 4 versus 2 patienter i micafungin - og fluconazol- grupperne.
Breakthrough Aspergillus infections were observed in 1 versus 7 patients, and proven or probable breakthrough Candida infections were observed in 4 versus 2 patients in the micafungin and fluconazole groups, respectively.